Results 81 to 90 of about 40,773 (330)
British medical journal, 2022 Clinical question In adults with low density lipoprotein (LDL) cholesterol levels >1.8 mmol/L (>70 mg/dL) who are already taking the maximum dose of statins or are intolerant to statins, should another lipid-lowering drug be added, either a proprotein ...
Q. Hao +26 more
semanticscholar +1 more source
Are PCSK9 Inhibitors Cost Effective? [PDF]
PharmacoEconomics, 2018 The objective of this study was to review available health economic evaluations of PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitors. These drugs reduce low-density lipid cholesterol levels and cardiovascular risk, but their cost effectiveness has been questioned. We searched Medline and Embase for economic evaluations in any language at
Max J. Korman +5 more
openaire +6 more sources
Atherosclerosis Plus, 2021 Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels.
Maria Giovanna Lupo +11 more
doaj
Arthritis Research & Therapy, 2021 Background Proprotein convertase subtilisin kexin 9 (PCSK9) targets the LDL-receptor (LDLR) which raises LDL-levels. In addition, PCSK9 has proinflammatory immunological effects.
Johan Frostegård +4 more
doaj +1 more source
Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials. [PDF]
, 2018 AimsThis analysis assessed the efficacy and safety of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in patients with or without metabolic syndrome (MetS) using pooled data from 10 phase 3 ODYSSEY trials.Materials and methodsData ...
Bujas-Bobanovic, Maja +6 more
core +1 more source
ACS Applied Materials and Interfaces, 2022 Compared with the traditional single therapy, nanomedicine has promoted a multimodal combination treatment for various carcinomas, especially the development of corresponding intelligent multifunctional biomaterials based on advanced DNA nanotechnology ...
Wenjing Guo +7 more
semanticscholar +1 more source
Biomedicine & Pharmacotherapy, 2022 annually in Europe, 4 million people die from cardiovascular diseases, the main cause of which is atherosclerosis. In order to slow down the development of atherosclerotic plaques, the main therapeutic goal is to lower LDL cholesterol (LDL-C) level. Undoubtedly, statins are the basis of lipid-lowering therapy for many years.
Grzegorz, Grześk +6 more
openaire +2 more sources
Genotype‐driven NPC1L1 and PCSK9 inhibition and reduced risk of periodontitis
Journal of Clinical Periodontology, Volume 50, Issue 1, Page 114-120, January 2023., 2023 Abstract Aim Epidemiological and pre‐clinical studies suggest a chemoprotective role of lipid‐lowering agents in periodontitis. We tested the association of genetically proxied inhibition of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase (HMGCR), Niemann‐Pick C1‐Like 1 (NPC1L1) and proprotein convertase subtilisin/kexin type 9 (PCSK9) with ...
Sebastian‐Edgar Baumeister +7 more
wiley +1 more source
Natriuretic Peptides in the Cardiovascular System. Multifaceted Roles in Physiology, Pathology and Therapeutics [PDF]
, 2019 The natriuretic peptides (NPs) family includes a class of hormones and their receptors needed for the physiological control of cardiovascular functions. The discovery of NPs provided a fundamental contribution into our understanding of the physiological ...
Rubattu, Speranza, Volpe, Massimo
core +1 more source
Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy. [PDF]
, 2021 Direct-acting antivirals (DAAs) efficiently eradicate the hepatitis C virus (HCV). Low-density lipoprotein (LDL) levels increase rapidly upon DAA treatment.
Buechler, Christa +6 more
core +2 more sources